TRIM8: A Ring-Type E3 Ubiquitin Transferase for Drug Targets and Biomarkers

Target Name: TRIM8

NCBI ID: G81603

TRIM8

TRIM8: A Ring-Type E3 Ubiquitin Transferase for Drug Targets and Biomarkers

Introduction

TRIM8 is a ring-type E3 ubiquitin transferase that is expressed in various tissues, including liver, muscle, and tests. It plays a crucial role in the regulation of protein degradation and is involved in a wide range of cellular processes, including cell growth, apoptosis, and autophagy. TRIM8 has also been implicated in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a result, targeting TRIM8 has been identified as a promising strategy for the development of new drugs and biomarkers.

Diseases associated with TRIM8

TRIM8 has been implicated in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. In cancer, TRIM8 has been shown to play a negative role in the regulation of apoptosis, which is the process by which cells undergo programmed cell death. Studies have shown , TRIM8 promotes the survival of cancer cells by regulating the degradation of proteins that are involved in cell apoptosis.

TRIM8 has also been linked to a number of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells and are thought to be caused by the build-up of toxic proteins. TRIM8 has been shown to be involved in the regulation of the degradation of proteins that are involved in neurodegeneration, which may contribute to the development and progression of these conditions.

In addition to its role in disease, TRIM8 has also been shown to be a potential biomarker for several diseases. The degradation of proteins that are involved in TRIM8 activity can be detected in a variety of tissues, including brain, muscle, and liver. This makes TRIM8 a potentially useful biomarker for diseases associated with protein degradation, such as cancer, neurodegenerative diseases, and autoimmune disorders.

Targeting TRIM8

Targeting TRIM8 has been identified as a promising strategy for the development of new drugs and biomarkers. One approach to targeting TRIM8 is to use small molecules that can inhibit its activity. These small molecules can be designed to interact with specific TRIM8 domains, such as the E3 ubiquitin transferase domain, to disrupt its function.

Another approach to targeting TRIM8 is to use antibodies that recognize and label TRIM8. These antibodies can be used to either block or activate TRIM8, depending on the desired effect. Using antibodies against TRIM8 has been shown to be effective in both preclinical and clinical settings, with some studies showing that treatment with antibodies against TRIM8 can reduce the expression of TRIM8 in cancer cells.

Tracking TRIM8

TRIM8 is a protein that is expressed in a variety of tissues and has been shown to play a role in several cellular processes. As a result, tracking TRIM8 can be difficult, as it is expressed in a diffuse manner in many tissues and can be difficult to detect using traditional techniques.

One approach to tracking TRIM8 is to use RNA sequencing (RNA-seq) to identify the expression of TRIM8 in different tissues and cells. RNA-seq is a powerful tool that allows researchers to identify the expression of any gene in a sample and to quantify the expression of each gene. By using RNA-seq to track TRIM8 expression, researchers have been able to identify the levels of TRIM8 in different tissues and cells and to determine its localization to specific cellular processes.

Another approach to tracking TRIM8 is to use immunofluorescence to visualize TRIM8 in different tissues and cells. Immunofluorescence is a technique that allows researchers to visualize specific proteins in different tissues and cells using antibodies that recognize the protein. By using antibodies against TRIM8, researchers have been able to visualize the localization of TRIM8 to specific cellular processes in different tissues

Protein Name: Tripartite Motif Containing 8

Functions: E3 ubiquitin-protein ligase that participates in multiple biological processes including cell survival, differentiation, apoptosis, and in particular, the innate immune response (PubMed:27981609, PubMed:28747347). Participates in the activation of interferon-gamma signaling by promoting proteasomal degradation of the repressor SOCS1 (PubMed:12163497). Plays a positive role in the TNFalpha and IL-1beta signaling pathways. Mechanistically, induces the 'Lys-63'-linked polyubiquitination of MAP3K7/TAK1 component leading to the activation of NF-kappa-B (PubMed:22084099, PubMed:23152791, PubMed:27981609, PubMed:34871740). Modulates also STAT3 activity through negative regulation of PIAS3, either by degradation of PIAS3 through the ubiquitin-proteasome pathway or exclusion of PIAS3 from the nucleus (PubMed:20516148). Negatively regulates TLR3/4-mediated innate immune response by catalyzing 'Lys-6'- and 'Lys-33'-linked polyubiquitination of TICAM1 and thereby disrupting the TICAM1-TBK1 interaction (PubMed:28747347)

The "TRIM8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRIM8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets